Copyright Reports & Markets. All rights reserved.

Global Chemotherapy-Induced Neutropenia Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Antibiotic Therapy
      • 1.4.3 Colony-Stimulating Factor Therapy
      • 1.4.4 Granulocyte Transfusion
      • 1.4.5 Splenectomy Procedure
      • 1.4.6 Others
    • 1.5 Market by Application
      • 1.5.1 Global Chemotherapy-Induced Neutropenia Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospital Pharmacy
      • 1.5.3 Retail Pharmacy
      • 1.5.4 Online Pharmacy
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Chemotherapy-Induced Neutropenia Treatment Market Size
    • 2.2 Chemotherapy-Induced Neutropenia Treatment Growth Trends by Regions
      • 2.2.1 Chemotherapy-Induced Neutropenia Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Chemotherapy-Induced Neutropenia Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Chemotherapy-Induced Neutropenia Treatment Market Size by Manufacturers
      • 3.1.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Manufacturers (2014-2018)
      • 3.1.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Manufacturers (2014-2018)
      • 3.1.3 Global Chemotherapy-Induced Neutropenia Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Chemotherapy-Induced Neutropenia Treatment Key Players Head office and Area Served
    • 3.3 Key Players Chemotherapy-Induced Neutropenia Treatment Product/Solution/Service
    • 3.4 Date of Enter into Chemotherapy-Induced Neutropenia Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size by Type (2014-2019)
    • 4.2 Global Chemotherapy-Induced Neutropenia Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Chemotherapy-Induced Neutropenia Treatment Market Size (2014-2019)
    • 5.2 Chemotherapy-Induced Neutropenia Treatment Key Players in United States
    • 5.3 United States Chemotherapy-Induced Neutropenia Treatment Market Size by Type
    • 5.4 United States Chemotherapy-Induced Neutropenia Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Chemotherapy-Induced Neutropenia Treatment Market Size (2014-2019)
    • 6.2 Chemotherapy-Induced Neutropenia Treatment Key Players in Europe
    • 6.3 Europe Chemotherapy-Induced Neutropenia Treatment Market Size by Type
    • 6.4 Europe Chemotherapy-Induced Neutropenia Treatment Market Size by Application

    7 China

    • 7.1 China Chemotherapy-Induced Neutropenia Treatment Market Size (2014-2019)
    • 7.2 Chemotherapy-Induced Neutropenia Treatment Key Players in China
    • 7.3 China Chemotherapy-Induced Neutropenia Treatment Market Size by Type
    • 7.4 China Chemotherapy-Induced Neutropenia Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Chemotherapy-Induced Neutropenia Treatment Market Size (2014-2019)
    • 8.2 Chemotherapy-Induced Neutropenia Treatment Key Players in Japan
    • 8.3 Japan Chemotherapy-Induced Neutropenia Treatment Market Size by Type
    • 8.4 Japan Chemotherapy-Induced Neutropenia Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Chemotherapy-Induced Neutropenia Treatment Market Size (2014-2019)
    • 9.2 Chemotherapy-Induced Neutropenia Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Chemotherapy-Induced Neutropenia Treatment Market Size by Type
    • 9.4 Southeast Asia Chemotherapy-Induced Neutropenia Treatment Market Size by Application

    10 India

    • 10.1 India Chemotherapy-Induced Neutropenia Treatment Market Size (2014-2019)
    • 10.2 Chemotherapy-Induced Neutropenia Treatment Key Players in India
    • 10.3 India Chemotherapy-Induced Neutropenia Treatment Market Size by Type
    • 10.4 India Chemotherapy-Induced Neutropenia Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Chemotherapy-Induced Neutropenia Treatment Market Size (2014-2019)
    • 11.2 Chemotherapy-Induced Neutropenia Treatment Key Players in Central & South America
    • 11.3 Central & South America Chemotherapy-Induced Neutropenia Treatment Market Size by Type
    • 11.4 Central & South America Chemotherapy-Induced Neutropenia Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Amgen
      • 12.1.1 Amgen Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.1.4 Amgen Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.1.5 Amgen Recent Development
    • 12.2 Sanofi
      • 12.2.1 Sanofi Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.2.4 Sanofi Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.2.5 Sanofi Recent Development
    • 12.3 Novartis
      • 12.3.1 Novartis Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.3.4 Novartis Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.3.5 Novartis Recent Development
    • 12.4 Baxter International
      • 12.4.1 Baxter International Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.4.4 Baxter International Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.4.5 Baxter International Recent Development
    • 12.5 Teva Pharmaceuticals Industries
      • 12.5.1 Teva Pharmaceuticals Industries Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.5.4 Teva Pharmaceuticals Industries Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.5.5 Teva Pharmaceuticals Industries Recent Development
    • 12.6 Apotex
      • 12.6.1 Apotex Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.6.4 Apotex Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.6.5 Apotex Recent Development
    • 12.7 Dr.Reddy’S Laboratory
      • 12.7.1 Dr.Reddy’S Laboratory Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.7.4 Dr.Reddy’S Laboratory Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.7.5 Dr.Reddy’S Laboratory Recent Development
    • 12.8 Biogenomics
      • 12.8.1 Biogenomics Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.8.4 Biogenomics Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.8.5 Biogenomics Recent Development
    • 12.9 Ligand Pharmaceuticals
      • 12.9.1 Ligand Pharmaceuticals Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.9.4 Ligand Pharmaceuticals Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.9.5 Ligand Pharmaceuticals Recent Development
    • 12.10 NAL Pharmaceuticals
      • 12.10.1 NAL Pharmaceuticals Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Chemotherapy-Induced Neutropenia Treatment Introduction
      • 12.10.4 NAL Pharmaceuticals Revenue in Chemotherapy-Induced Neutropenia Treatment Business (2014-2019)
      • 12.10.5 NAL Pharmaceuticals Recent Development
    • 12.11 Coherus BioSciences
    • 12.12 Intas Pharmaceuticals

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Chemotherapy is widely used as to target the neoplastic cells. However, this therapy is effective against most of the cancer, but the cells of the hematopoietic system that produces billions of blood cells needed daily are highly sensitive to this therapy and result in loss of blood cell population. This condition is known as the chemotherapy-induced neutropenia. In chemotherapy-induced neutropenia, the body has a low level of neutrophils which are types of white blood cells. Neutrophils are body’s defense system against infections. Neutrophils fight against infection by destroying fungi, bacteria or yeast. Neutropenia occurs in about half of the people receiving chemotherapy. People with chemotherapy-induced neutropenia are most likely to develop infection and fever. It can also lead to delay in treatment and reduction in chemotherapy dose intensity. Chemotherapy-induced neutropenia is most likely to occur in cancer that directly affects the bone marrow such as leukemia. Chemotherapy-induced neutropenia patients mostly require hospitalization and cost of the treatment also increase with the anti-infective treatment.
      Chemotherapy is the most preferred choice of treatment for cancer. Increasing use of chemotherapy will drive the growth of chemotherapy-induced neutropenia treatment market.
      In 2018, the global Chemotherapy-Induced Neutropenia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Chemotherapy-Induced Neutropenia Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Chemotherapy-Induced Neutropenia Treatment development in United States, Europe and China.

      The key players covered in this study
      Amgen
      Sanofi
      Novartis
      Baxter International
      Teva Pharmaceuticals Industries
      Apotex
      Dr.Reddy’S Laboratory
      Biogenomics
      Ligand Pharmaceuticals
      NAL Pharmaceuticals
      Coherus BioSciences
      Intas Pharmaceuticals

      Market segment by Type, the product can be split into
      Antibiotic Therapy
      Colony-Stimulating Factor Therapy
      Granulocyte Transfusion
      Splenectomy Procedure
      Others

      Market segment by Application, split into
      Hospital Pharmacy
      Retail Pharmacy
      Online Pharmacy

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Chemotherapy-Induced Neutropenia Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Chemotherapy-Induced Neutropenia Treatment development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Chemotherapy-Induced Neutropenia Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now